NCEL (NewcelX) Total Liabilities: $4.20 Mil (As of Dec. 2025)


NCEL NewcelX Ltd NCEL
33 GF Score
Price $3.83
! 4 Warning Signs
View Full Analysis

What is NewcelX Total Liabilities?

NewcelX NCEL -0.52% 33 Total Liabilities is $4.20 Mil as of Dec. 2025. GuruFocus rates NCEL with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

NewcelX's Total Liabilities for the quarter that ended in Dec. 2025 was $4.20 Mil.

NewcelX's quarterly Total Liabilities increased from Dec. 2024 ($8.90 Mil) to Jun. 2025 ($15.49 Mil) but then declined from Jun. 2025 ($15.49 Mil) to Dec. 2025 ($4.20 Mil).

NewcelX's annual Total Liabilities increased from Dec. 2023 ($3.35 Mil) to Dec. 2024 ($8.90 Mil) but then declined from Dec. 2024 ($8.90 Mil) to Dec. 2025 ($4.20 Mil).

NewcelX Total Liabilities Historical Data

* Premium members only.

The historical data trend for NewcelX's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewcelX Total Liabilities Chart

NewcelX Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.85 3.45 3.35 8.90 4.20

NewcelX Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.35 3.59 8.90 15.49 4.20
NCEL
33GF Score
NewcelX Ltd NCEL
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewcelX Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NewcelX's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.195+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.20

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=11.445-7.25
=4.20

NewcelX's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.195+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.20

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=11.445-7.25
=4.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $4.20 Mil mean?
NewcelX (NCEL) has a Total Liabilities of $4.20 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NewcelX and its competitors.
Is NewcelX's Total Liabilities too high?
NewcelX's current Total Liabilities is $4.20 Mil. Overall, NewcelX has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NewcelX's Total Liabilities compare to LPCN and PTN?
NewcelX's Total Liabilities of $4.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NewcelX and its competitors. NewcelX's current Total Liabilities is $4.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewcelX stock overvalued right now?
NewcelX (NCEL) has a current Total Liabilities of $4.20 Mil. The current Total Liabilities is $4.20 Mil. NewcelX's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For NewcelX (NCEL), the current Total Liabilities is $4.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NewcelX Business Description

Address Hohstrasse 1, Kloten, CHE, 8302
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
33GF Score

Get the complete analysis for NCEL

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price